A vaccine has been shown to help reduce the number of infants and toddlers developing frequent ear infections, according to new research from Katherine A. Poehling, M.D., a pediatrician at Brenner Children?s Hospital, part of Wake Forest University Baptist Medical Center.
Health services in many developing countries are weak and there is a shortage of skilled health professionals. There is a need, therefore, to ensure that male circumcision services for HIV prevention do not unduly disrupt other health care programmes, including other HIV/AIDS interventions.
MeritCare Outpatient Dialysis Services, Fargo, N.D., and Detroit Lakes, Minn., has received a $7,500 grant from Dakota Medical Foundation (DMF) to help support its nutritional supplement program.
Cephalon, Inc. (Nasdaq: CEPH) announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).
A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) and Harvard Medical School has identified seven genetic risk factors?DNA sequences carried by some people but not others?that predict risk for prostate cancer.
In the past week, national figures Elizabeth Edwards and Tony Snow have brought much needed focus on the diagnosis and treatment of cancer. The challenge is to overcome patient fear and encourage qualified second opinions.
Inherent gender differences — instead of more sun exposure — may be one reason why men are three times more likely than women to develop certain kinds of skin cancer, say researchers at Ohio State University Medical Center.
Roche announced that their innovative cancer drug Avastin (bevacizumab) has been approved in Europe for the treatment of women with metastatic breast cancer.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug.
The BMA is launching updated guidance on withholding and withdrawing life-prolonging treatment, to take into account the major changes for patients and doctors that will come into force when the Mental Capacity Act is implemented in England and Wales in April and October 2007.